



ASX ANNOUNCEMENT

6 December 2021

## Results of November Options Exercise and Closeout of CDXO Option Campaign

### Highlights:

- Strong shareholder take up in CDXO and unlisted November Options with 92.82% total conversion raising \$7,666,510;
- C2V and CDX Board Directors who held CDXO and other Options exercised over 40,000,000 Options to the full capacity allowed within compliance;
- CardieX in a strong financial position to pursue growth initiatives across the Company's medical and consumer device divisions.

### *CDXO and 30 November 2021 Option Expiry*

CardieX Limited (ASX:CDX) (**CardieX**, the **Company**) is pleased to provide an update on the recent exercise and otherwise expiry of CDXO Listed Options (ASX:CDXO), and unlisted Options, which were both exercisable at \$0.05 and expired on 30 November 2021 (together the "**November Options**").

Of the 127,675,656 listed CDXO Options and 37,500,000 unlisted options on issue, being a total of 165,175,656 November Options, 153,330,197 were fully exercised by November Option holders, raising a total of \$7,666,510, representing a conversion of 92.82%.

The Company is lodging the requisite Appendix 2A, Appendix 3Y's for Directors, and all other documents/other issuing documentation later today, in compliance with the ASX listing rules and related option conversion/share issuance requirements.

### *Board Support and Participation in Option Exercise*

The Board of the Company is also pleased to advise that C2 Ventures Pty Ltd ("C2V"), an entity controlled jointly by Craig Cooper (CEO) and Niall Cairns (Chairman), has exercised 2,420,455 listed CDXO Options and 37,500,000 unlisted Options at \$0.05, representing a \$1,996,023 contribution to the working capital of CardieX.

All Directors have exercised all of their Options available for conversion taking total Board participation inclusive of C2V well in excess of \$2,000,000 of the total November Options exercise.



### ***CardieX in Strong Financial Position to Pursue Growth Initiatives***

The funds raised through the exercise of Options will be used to accelerate the Company's new product development and go-to-market strategy, FDA clearances, partnerships, and other strategic initiatives across its medical and new consumer device divisions – including the world's first consumer "dual blood pressure monitor", the launch and go-to-market strategy surrounding the forthcoming Mobvoi watch partnership, as well as multiple wearable initiatives and new digital health solutions.

### **CardieX CEO, Craig Cooper, commented:**

"On behalf of the Board and management, I would like to thank you for the overwhelming support and the additional significant capital provided to the Company as a result of the exercise of CDXO Options by shareholders.

The coming months will continue to be transformational for the Company as we execute on our strategic vision and plan."

Approved by the Board of Directors and Released by Jarrod White, Director.

For more information please contact:

#### **Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

#### **Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

### **About CardieX**

CardieX is a global health technology company. Its ACTOR subsidiary is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Its CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Stock Exchange (ASX:CDX).